SpaceX Rocket Explodes Into Giant Fireball During Test At Texas Starbase Facility
SpaceX's Starship rocket exploded into a massive fireball while it was being prepared for a flight test at its Starbase testing facility in Texas on Wednesday night, marking the latest in a series of explosions that have marred the testing of the rocket company's most powerful launch vehicle.
FILE PHOTO- SpaceX's mega rocket Starship exploded during a test on Wednesday night.
The explosion took place around 11 p.m. CDT and was captured on SpaceX's livestream as the Starship rocket was being prepared for a flight test.
In a statement, the company said it was preparing the Starship for its tenth flight test when it 'experienced a major anomaly while on a test stand.'
SpaceX said the safety clear area around the rocket test site was 'maintained throughout the operation and all personnel are safe and accounted for.'
The company said there are 'no hazards to residents in surrounding communities,' but urged locals to ' not attempt to approach the area while safing operations continue.'
A spokesperson for the Brownsville Fire Department told ABC affiliate KRGV-TV that firefighters have been dispatched to the site of the explosion, but the full scale of the incident was unknown to them.
This is a developing story.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Medscape
an hour ago
- Medscape
Updates in Metastatic NSCLC From ASCO 2025
Dr Jonathan Goldman, of the University of California, Los Angeles, shares key updates in metastatic non-small cell lung cancer from ASCO 2025. Dr Goldman reviews findings from TROPION-Lung02, which evaluated datopotamab deruxtecan (Dato-DXd) ± pembrolizumab (pembro) in first-line metastatic NSCLC. The objective response rate (ORR) was 55% for Dato-DXd + pembro vs 56% for chemo. Improved outcomes in TROP2 NMR-positive patients may indicate a predictive biomarker. Dr Goldman then discusses results from OptiTROP-Lung03, in which sacituzumab tirumotecan (sac-TMT) showed superior efficacy compared to docetaxel in pretreated EGFR-mutated NSCLC. The ORR for sac-TMT was 45% vs 15% for docetaxel. Next, he highlights updates from KRYSTAL-7 of first-line adagrasib plus pembro in KRASG12C-mutant NSCLC. The combination yielded an ORR of 44% and median duration of response of 26.3 months. In patients with a PD-L1 ≥ 50%, ORR reached 50% vs 34% in those with lower expression. Dr Goldman also reports on HERTHENA-Lung02, in which patritumab deruxtecan (HER3-DXd) improved progression-free survival (PFS) vs chemo in resistant EGFR-mutated NSCLC, but the lack of overall survival benefit led to application withdrawal. Finally, Dr Goldman reviews phase 2b findings from REZILIENT1, evaluating zipalertinib in EGFR exon 20-mutant NSCLC. In patients without prior amivantamab, ORR was 40% and PFS was 9.5 months. In those previously treated with amivantamab, zipalertinib resulted in clinically meaningful results: an ORR of 23.5% and PFS of 7.3 months.
Yahoo
an hour ago
- Yahoo
Biotech industry faces off: US vs. China
China has become a significant player in the biotech space, potentially threatening the lead the US holds. EY Americas industry markets leader for health sciences and wellness Arda Ural sits down with Josh Lipton and Yahoo Finance Senior Reporter Anjalee Khemlani to discuss the dynamics between the US and China in the biotech industry. To watch more expert insights and analysis on the latest market action, check out more Market Domination Overtime here According to a recent report from the Harvard Belfer Center for Science and International Affairs, China has the most immediate opportunity to overtake the United States in biotechnology. For more, let's welcome in Arta Rawi America's industry markets leader and Health Sciences and wellness, as well as Yahoo Finance's very own Anjali Camlani. Welcome to you both. All right, I'll start with you. Uh, maybe it's just a big question, big picture question. Does the US have the investment power, in your opinion, to overtake China in biotech? Yeah, thanks for having me. Uh, the biotech is the innovation feeder to the big pharmaceuticals and it only uh nurtures well in an ecosystem. So to answer your question, what do you need in that ecosystem for that to nurture? Uh, investment capacity, which we have been having for the last, you know, decades, if you will, to kind of keep investing in that innovation to move on. NIH has been probably the world's largest VC over $40 billion in non-dilute funding into the entrepreneurial startups. Then you have talent who has been, you know, coming all these top universities and MDs and PhDs who are dedicated to advance it. And then you need this technology transfer system so that those intellectual property translate into a startup. And then with that investment capacity, it keeps growing and then through testing and going to the humans and then ultimately being developed for everyone's use. So, uh, yes, the US still has the capacity to invest, but it is not potentially the only game in town given the development coming from China. I'm curious, Arta, because we know, I know you've been tracking the deals and uh, we've seen the number of deals steadily increasing over the years. I saw, uh, one of the ones that you sent, which looks at the number of deals so far to date for 2025 is more than half of what we saw in 2024. So we can expect that to really outpace 2024. What does that mean though? Because I know that some of the deals that are happening are more, um, what you would call licensing deals, right? It's not necessarily that this money is going to from scratch investment and innovation, but it's more stuff that has already happened and is built up. Talk to me about that and why that matters. I mean, first of all, the numbers are pretty compelling. A couple years ago, we had pretty much like no deals under a billion dollars in 2016. And as of last year, there were $30 billion worth of licensing deals from Chinese assets into the US, and 2025 is a very strong start, so they're definitely going to beat that number. So the reason why this is happening is in 2015, Chinese Communist Party put a priority of investing in biotech and that was a priority sectors. And it was 10 years ago, and that 10 years of journey started to play out for their benefit because China historically has been known for this active product ingredients and excipients, which is like the chemicals that pharmaceuticals were using to make small molecule products. And that journey now is taking them to upstream to more advanced innovation. Probably we still have not seen a first in class, but clearly they are going for best in class, like those are the shots on goal if you are seeing more and more. Well, that's why, that would be my question because I know that we've seen sort of they're doing copycats or metoos in terms of the type of innovation coming out of China. Um, do we expect that they have the wherewithal to outdo the US then in that sense, in terms of coming up with the next blockbuster for the entire world? I mean, there are a couple examples, early examples that some of the Chinese based assets actually head-to-head comparisons, you know, beat or exceed, at least match the efficacy and safety profile of some of the Western developed compounds. But this is also a journey as the audio question. So what is it, what do they need more to get there? So they have the talent. I mean a lot of Western educated MDs and PhDs went back to China working on that. The government itself as a part of prioritization program have been investing in it. So then the question is, do they have an exit strategy for those entrepreneurs? And that I think is where they are lacking because there's no like an IPO market that is comparable to the Western standards. There's no like an M&A exit until recently. I think that's where the weakness kind of may be the opportunity for them to come up. But the deals we were talking about, they're because of the intellectual property concerns, because of the concerns of reliability and trust in the data because, you know, there's no such institution in the world like FDA that everyone trusts and hopefully continue to trust. And for that reason, the deals seem to be more asset purchases. So I'm not taking a risk by operating in China, but I'm buying the asset and in a licensing deal, and I'll continue to develop it, especially if you can make this cheaper and faster in China, which has been their competitive advantage over the Western companies, then you bring that into a human fast and then the human testing can be done, validations can be done in the more Western setting. I think that can be a winning formula for the industry. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 hours ago
- Yahoo
Rise in VC activity tees up ‘strong year' for medtech funding: PitchBook
This story was originally published on MedTech Dive. To receive daily news and insights, subscribe to our free daily MedTech Dive newsletter. Increases in venture capital investments have positioned 2025 to be a 'strong year for global medtech funding,' according to a report from market data research firm PitchBook. First quarter VC funding totaled $4.1 billion, the highest it has been since 2022. The number of confirmed transactions hit 216, reversing a four-quarter decline. However, the uptick in medtech mergers and acquisitions that PitchBook predicted under the second Trump administration has yet to emerge, and antitrust regulators are still challenging deals. Medtech VC activity fell in both 2022 and 2023, according to PitchBook. Last year brought signs that the market might be bottoming. The number of VC investments fell for the third year in a row, but the amount of funding was higher than in 2023. Signs of a VC recovery continued into the first quarter of 2025, when the $260 million investment in whole-body-imaging startup Neko Health was the largest of 11 rounds worth $100 million or more. With Elon Musk's brain implant startup Neuralink raising $650 million this month, PitchBook said preliminary data for the second quarter shows more than $3 billion of medtech VC funding so far. VC exits are rare, though. PitchBook said there were no significant medtech VC exits in the first quarter, and the total exit value remained roughly in line with the previous two quarters. Total exit value in recent years has been driven by rare big deals, such as Tempus AI's initial public offering in 2024 and the $6 billion acquisition of Athelas in 2023. PitchBook highlighted three notable exits that closed in the first quarter: Beta Bionics' IPO, Hologics' $350 million takeover of Gynesonics and Boston Scientific's $540 million acquisition of SoniVie. The level of activity has fallen short of PitchBook's expectations. 'Our earlier thesis that the new U.S. presidential administration's more lenient regulatory stance would catalyze M&A activity has yet to play out, as broader market turbulence in early 2025 has complicated dealmaking conditions across sectors,' PitchBook said. 'Additionally, regulatory resistance remains a headwind.' PitchBook cited the Federal Trade Commission's legal challenge to the $627 million private equity buyout of Surmodics as evidence of ongoing regulatory resistance. The FTC challenged the deal on the grounds it 'would lead to a highly concentrated market for outsourced hydrophilic coatings and eliminate significant head-to-head competition.' Recommended Reading Medtech venture investment recovery continues, but startup M&A remains limited: Pitchbook Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
